Abstract
To better understand the consistency in the role of inflammation in diabetic retinopathy (DR) and diabetic macular edema (DME) and the efficacy of injecting 0.19 mg fluocinolone acetonide (FAc) intravitreally to treat DME, a consensus survey report was drafted by 56 retinal disease experts from the United States. Doctors highly agreed on the role of inflammation in DR/DME pathophysiology, injection loading and patient compliance, as well as the efficacy and safety of FAc injections. However, no consensus has been established on the effect of FAc implants on DR progression, the efficacy of FAc as a baseline treatment for DME, and the effectiveness of steroid stimulation to reduce the risk of intraocular pressure after FAc use. This paper interprets the expert consensus, providing references for further research and application of FAc injections for DR/DME treatment.
| Translated title of the contribution | Specification on the fluocinolone acetonide treatment for patients with diabetic macular edema: interpretation of expert consensus 2023 |
|---|---|
| Original language | Chinese (Traditional) |
| Pages (from-to) | 757-760 |
| Number of pages | 4 |
| Journal | Recent Advances in Ophthalmology |
| Volume | 43 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 1 Oct 2023 |
Keywords
- diabetic macular edema
- diabetic retinopathy
- fluocinolone acetonide
- treatment
- consensus